This trial aims to find out how safe talazoparib (Talzenna) followed by a combination of talazoparib and avelumab (Bavencio) is in patients with advanced breast cancer. The main outcome that will be measured is if patients have side effects. This study is being conducted in Washington, the United States.
The details
Talazoparib and avelumab are anti-cancer medications. They are suspected to work well in breast cancer that is in the later stages. It is not known if using talazoparib, followed by talazoparib and avelumab will be safe in these patients.
This trial aims to find out how safe talazoparib followed by a combination of talazoparib and avelumab is in patients with advanced breast cancer. The main outcome that will be measured is if patients have side effects.
Who are they looking for?
The study is recruiting 24 patients with advanced breast cancer. The patients must have good liver, kidney and bone marrow function and a life expectancy of more than 3 months.
The patients must not have any other medical conditions such as a history of tuberculosis, active infections, a history of autoimmune disease or immunodeficiency. The patients cannot have been previously treated with medications similar to the study drugs. Patients must not be pregnant or breastfeeding and should not have cancer in the brain.
How will it work
All of the patients will receive the same treatment. Each patient will be treated with talazoparib for one cycle. For every cycle after that, they will be treated with talazoparib and avelumab together. Treatment will stop if the patients are too sick.
Patients will be followed for side effects and survival for up to 5 years.
